13F Pro13F Pro

Exome Asset Management LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 2011932
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$162.1M

AUM History

13fpro.ai/research/fund/exome-asset-management-llc-2011932

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/exome-asset-management-llc-2011932

Exome Asset Management LLC 13F holdings — Q2 2026

$162.1M portfolio (-16.2% QoQ) · 52 holdings · Q2 2026 13F · top 10 are 45% of the stock portfolio

All holdings — Exome Asset Management LLC (Q2 2026)

52 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
VERA$VERAVera Therapeutics, Inc.$4.2M-15%
UNH$UNHUNITEDHEALTH GROUP INC$4.0M-25%
TXG$TXG10x Genomics, Inc.$3.9M-33%
NTRA$NTRANatera, Inc.$3.7M-26%
QURE$QUREuniQure N.V.$3.7MNew
RYTM$RYTMRHYTHM PHARMACEUTICALS, INC.$3.6M-21%
MAZE$MAZEMaze Therapeutics, Inc.$3.4M+30%
GLUE$GLUEMonte Rosa Therapeutics, Inc.$3.3M-24%
MLTX$MLTXMoonLake Immunotherapeutics$3.2M-23%
ALKS$ALKSAlkermes plc.$3.2M-27%
LQDA$LQDALiquidia Corp$3.1M-14%
UTHR$UTHRUNITED THERAPEUTICS Corp$2.9M-23%
GKOS$GKOSGLAUKOS Corp$2.8M-5%
ARWR$ARWRARROWHEAD PHARMACEUTICALS, INC.$2.6M-30%
AGIO$AGIOAGIOS PHARMACEUTICALS, INC.$2.6M-44%

What changed in Q2 2026

Against the previous quarter's 13F: 15 new, 1 added to, 32 trimmed, 19 sold out. Share-count changes; largest moves by dollar size first.

New positions (15)

  • TGTX$TGTXTG THERAPEUTICS, INC.$9.1M

    first bought this quarter

  • ABVX$ABVXAbivax S.A.$6.2M

    first bought this quarter

  • QURE$QUREuniQure N.V.$3.7M

    first bought this quarter

  • AZN$AZNASTRAZENECA PLC$2.3M

    first bought this quarter

  • VKTX$VKTXViking Therapeutics, Inc.$1.9M

    first bought this quarter

  • OCUL$OCULOCULAR THERAPEUTIX, INC$1.8M

    first bought this quarter

+9 more in the Excel export

Added to (1)

  • MAZE$MAZEMaze Therapeutics, Inc.+30%

    now $3.4M · held 2 qtrs, 2 adds in a row

Trimmed (32)

  • PRAX$PRAXPraxis Precision Medicines, Inc.-40%

    now $9.1M · held 4+ qtrs, 3 trims in a row

  • ELVN$ELVNEnliven Therapeutics, Inc.-54%

    now $5.1M · held 3 qtrs

  • RLAY$RLAYRelay Therapeutics, Inc.-83%

    now $889K · held 2 qtrs

  • CYTK$CYTKCYTOKINETICS INC-42%

    now $5.1M · held 4+ qtrs, 3 trims in a row

  • BBIO$BBIOBridgeBio Pharma, Inc.-73%

    now $1.4M · held 4+ qtrs, 3 trims in a row

  • COGT$COGTCogent Biosciences, Inc.-24%

    now $8.1M · held 4+ qtrs, 3 trims in a row

+26 more in the Excel export

Sold out (19)

  • PUTSPDR SERIES TRUSTwas $7.7M
  • ELV$ELVElevance Health, Inc.was $4.3M

    held 2 qtrs

  • CYTK$CYTKPUTCYTOKINETICS INCwas $4.0M
  • APLS$APLSApellis Pharmaceuticals, Inc.was $3.4M

    held 2 qtrs

  • ONC$ONCCALLBeOne Medicines Ltd.was $3.0M
  • AVTX$AVTXAvalo Therapeutics, Inc.was $2.4M

    held 1 qtr

+13 more in the Excel export

Firm AUM (Form ADV): $548.6M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Exome Asset Management LLC has filed, 10 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Exome Asset Management?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Exome Asset Management's top 20 holdings: 43/100 (our AI quality score, weighted by position size; 12 of the 20 are scored)

Top 10 since filing

-15.7%

Value-weighted move of the 10 largest stock positions

Turnover

22%

Last quarter

Top 10 weight

45%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

53%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q3 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Exome Asset Management LLC disclosed 52 positions worth $162.1M in its Form 13F-HR for Q2 2026, led by $GH (Guardant Health, Inc.) at 6.3% of the equity portfolio, followed by $PRAX and $TGTX. During the quarter the fund opened 15 new positions and exited 19 — including a new stake in $TGTX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Exome Asset Management LLC’s Form 13F-HR filing with the SEC under CIK 2011932.

Funds like this

managers whose biggest positions overlap Exome Asset Management's
Deep Track Capital, LP$6.87B 13F book · 11 shared top holdingsGHALMSIONSVERAVestal Point Capital, LP$4.28B 13F book · 11 shared top holdingsABVXELVNGLUEUTHRLogos Global Management LP$2.32B 13F book · 9 shared top holdingsABVXPRAXVERAMAZEORBIMED ADVISORS LLC$5.40B 13F book · 10 shared top holdingsELVNABVXGHQUREDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 7 shared top holdingsPRAXIONSCOGTVERAEversept Partners, LP$1.93B 13F book · 10 shared top holdingsABVXIONSVERANTRA

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Exome Asset Management LLC

13F Pro is an AI hedge fund tracker and stock research platform. For Exome Asset Management LLC (SEC CIK: 2011932), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Exome Asset Management LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.